An observational study in Myasthenic Syndromes, Congenital, sponsored by National Institute of Neurological Disorders and Stroke (NINDS). Recruiting at 1 site in United States. Open to participants aged 6 Months to 99 Years. Per ClinicalTrials.gov, last updated 2026-08-13.
Sponsored by National Institute of Neurological Disorders and Stroke (NINDS) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Background:
Congenital myasthenic syndromes (CMSs) are a group of inherited disorders that affect how the nerves communicate with muscles. These can cause many problems that affect how people can move and use their bodies.
Objective:
This is a natural history study to learn more about how CMSs affect the body and cause changes over time.
Eligibility:
People aged 6 months or older with a CMS. The study will focus on DOK7- and COLQ-related CMSs, as well as other forms.
Design:
Participants will have up to 7 visits in 5 years. At each visit, participants will undergo many tests, including:
Physical exam with blood and urine tests.
Tests of their heart and lung function.
Exams of the eyes, lungs, muscles, and nerves. These will be done with different specialists.
Exams of the arms and hands and of body use and movements. These will also be done with specialists.
Photos and videos may be taken.
Muscle ultrasound. Participants will lie still as a wand is rubbed over their skin.
Magnetic resonance imaging (MRI) scans. Participants will lie still on a bed that slides partway into a large tube. A parent or other person may remain in the room, too. The scan will take 60 minutes.
Electromyography (EMG). Participants will lie still or may be asked to move around. A machine will measure the electrical activity in their muscles.
An activity monitor may be placed on the participant s wrist, ankle, or hip for up to 2 weeks. The monitor is about the size of a wristwatch.
A sample of skin may be removed....
Study Description:
This natural history and outcome measure validation study aims to longitudinally characterize the clinical manifestations of all congenital myasthenic syndromes (CMS), with a focus on DOK7 and COLQ-related CMS. Both are ultra-rare inherited disorders of the neuromuscular junction. This study will also assess the validity and interrater reliability of outcome measures to support clinical trial readiness in these populations.
Primary Objective:
Characterize baseline clinical manifestations and CMS disease course over one year.
Co-Primary Objective:
Assess the validity and interrater reliability of outcome measures in CMS.
Secondary Objectives:
Characterize the extended disease course of CMS (Years 2 through 5)
Exploratory Objectives:
Biomarker identification, accelerometer validation, and MCID estimation.
Primary Endpoints:
Change from baseline to Year 1 in the following (as age-appropriate and tolerated-performed in all participants unless age ranges specified):
Physical strength
Physical performance
Disease severity
--Quantitative Myasthenia Gravis (QMG) Score (>= 12y)
Motor function \<2y
Motor function >2y
Development
--Developmental motor scale quotients (\<5y)
Pulmonary function >=5y
Quality of life
Serious adverse and disease-related events
Co-Primary Endpoints:
Interrater reliability in physical strength, physical performance, motor function, and quality of life primary endpoints.
Secondary Endpoints:
Change over time in primary endpoints (Years 2 through 5).
Exploratory Endpoints:
Physical performance
Biomechanics
Free-living physical activity
Ophthalmology
Quality of life
Biomarkers
Imaging
Nerve function
--EMG/NCS (sfEMG and RNS)
Measurement of AE burden
National Institute of Neurological Disorders and Stroke (NINDS) is the lead sponsor of 601 studies on the registry; 56 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 8 (44%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with congenital myasthenic syndromes with a focus on DOK7 and COLQ subtypes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
EXCLUSION CRITERIA:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Genetically confirmed COLQ-related CMS
Characterize baseline clinical manifestations and CMS disease
Time frame: One year
Assess the validity and interrater reliability of outcome measures in CMS
Time frame: 5 Years
Characterize the extended disease course of CMS
Time frame: Years 2-5
Plan to share: No
Started May 2025 (actual). Primary completion is estimated for Dec 2042, 210 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Myasthenic Syndromes, Congenital
National Institute of Neurological Disorders and Stroke (NINDS) →